Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B-encapsulated nanoemulsion template-based chitosan nanocapsules

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 4, 2013, Pages 1714-1722

  Asthana, Shalini ^a   Jaiswal, Anil K ^a   Gupta, Pramod K ^a   Pawar, Vivek K ^a   Dube, Anuradha ^a   Chourasia, Manish K ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CHITOSAN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; MESSENGER RNA; NANOCAPSULE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT CHEMOTHERAPY; ANIMAL CELL; ARTICLE; DOWN REGULATION; DRUG FORMULATION; ERYTHROCYTE; HAMSTER; IC 50; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA DONOVANI; MALE; NANOEMULSION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; VISCERAL LEISHMANIASIS;

AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; CHITOSAN; CRICETINAE; LEISHMANIASIS, VISCERAL; MALE; NANOCAPSULES;

EID: 84875148599     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01984-12     Document Type: Article

References (54)

1. World Health Organization. 2010. Control of the leishmaniases: report of a meeting of theWHOExpert Committee on the Control of Leishmaniases, Geneva, 22-26 March 2010, p 5-12. Technical report series 949. World Health Organization, Geneva, Switzerland.
2. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, Alvar J, Boelaert M. 2007. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol. 5:873- 882.
3. Malla N, Mahajan RC. 2006. Pathophysiology of visceral leishmaniasis - some recent concepts. Indian J. Med. Res. 123:267-274.
4. Handman E. 2001. Leishmaniasis: current status of vaccine development. Clin. Microbiol. Rev. 14:229 -243.
5. World Health Organization. 2010. Control of the leishmaniases: report of a meeting of theWHOExpert Committee on the Control of Leishmaniases, Geneva, 22-26 March 2010, p 104. Technical report series 949. World Health Organization, Geneva, Switzerland.
6. Pourshafie M, Morand S, Virion A, Rakotomanga M, Dupuy C, Loiseau PM. 2004. Cloning of S-adenosyl-L-methionine:C-24-Δ-sterolmethyltransferase (ERG6) from Leishmania donovani and characterization of mRNAs in wild-type and amphotericin B-resistant promastigotes. Antimicrob. Agents Chemother. 48:2409 -2414.
7. Dupont B. 2002. Overview of the lipid formulations of amphotericin B. J. Antimicrob. Chemother. 49(Suppl. 1):31-36.
8. Townsend RW, Zutshi A, Bekersky I. 2001. Biodistribution of 4-[14C]cholesterol-AmBisome following a single intravenous administration to rats. Drug Metab. Dispos. 29:681- 685.
9. Sánchez-Brunete JA, Dea MA, Rama S, Bolas F, Alunda JM, Torrado- Santiago S, Torrado JJ. 2004. Amphotericin B molecular organization as an essential factor to improve activity/toxicity ratio in the treatment of visceral leishmaniasis. J. Drug Target. 12:453- 460.
10. Hiemenz JW, Walsh TJ. 1996. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22(Suppl. 2):S133-S144.
11. Wong-Beringer A, Jacobs RA, Guglielmo BJ. 1998. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis. 27:603-618.
12. Chandy T, Sharma CP. 1990. Chitosan - as a biomaterial. Biomater. Artif. Cells Artif. Organs 18:1-24.
13. Dornish M, Kaplan DS, Arepalli SR. 2012. Regulatory status of chitosan and derivatives, p 463-481. In Sarmento B, das Neves J (ed), Chitosanbased systems for biopharmaceuticals: delivery, targeting and polymer therapeutics, 1st ed, vol 1.Wiley, Chichester, West Sussex, United Kingdom.
14. Peluso G, Petillo O, Ranieri M, Santin M, Ambrosio L, Calabro D, Avallone B, Balsamo G. 1994. Chitosan-mediated stimulation of macrophage function. Biomaterials 15:1215-1220.
15. Kushawaha PK, Gupta R, Sundar S, Sahasrabuddhe AA, Dube A. 2011. Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN- and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge. J. Immunol. 187:6417- 6427.
16. Seo WG, Pae HO, Kim NY, Oh GS, Park IS, Kim YH, Lee YH, Jun CD, Chung HT. 2000. Synergistic cooperation between water-soluble chitosan oligomers and interferon-gamma for induction of nitric oxide synthesis and tumoricidal activity in murine peritoneal macrophages. Cancer Lett. 159:189 -195.
17. Yu Z, Zhao L, Ke H. 2004. Potential role of nuclear factor-κB in the induction of nitric oxide and tumor necrosis factor-alpha by oligochitosan in macrophages. Int. Immunopharmacol. 4:193-200.
18. Shibata Y, Metzger WJ, Myrvik QN. 1997. Chitin particle-induced cellmediated immunity is inhibited by soluble mannan: mannose receptormediated phagocytosis initiates IL-12 production. J. Immunol. 159:2462-2467.
19. Otterlei M, Varum KM, Ryan L, Espevik T. 1994. Characterization of binding and TNF-α-inducing ability of chitosans on monocytes: the involvement of CD14. Vaccine 12:825- 832.
20. Feng J, Zhao L, Yu Q. 2004. Receptor-mediated stimulatory effect of oligochitosan in macrophages. Biochem. Biophys. Res. Commun. 317: 414-420.
21. Ogawa S, Decker EA, McClements DJ. 2003. Production and characterization of O/W emulsions containing cationic droplets stabilized by lecithin-chitosan membranes. J. Agric. Food Chem. 51:2806 -2812.
22. Dube A, Singh N, Sundar S. 2005. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitol. Res. 96:216 -223.
23. Kaur J, Sundar S, Singh N. 2010. Molecular docking, structure-activity relationship and biological evaluation of the anticancer drug monastrol as a pteridine reductase inhibitor in a clinical isolate of Leishmania donovani. J. Antimicrob. Chemother. 65:1742-1748.
24. Garg R, Gupta SK, Tripathi P, Hajela K, Sundar S, Naik S, Dube A. 2006. Leishmania donovani: identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis. Vaccine 24:2900 -2909.
25. Martini E, Fattal E, de Oliveira MC, Teixeira H. 2008. Effect of cationic lipid composition on properties of oligonucleotide/emulsion complexes: physico-chemical and release studies. Int. J. Pharm. 352:280 -286.
26. Paiphansiri U, Tangboriboonrat P, Landfester K. 2006. Polymeric nanocapsules containing an antiseptic agent obtained by controlled nanoprecipitation onto water-in-oil miniemulsion droplets. Macromol. Biosci. 6:33- 40.
27. Chourasia MK, Kang L, Chan SY. 2011. Nanosized ethosomes bearing ketoprofen for improved transdermal delivery. Results Pharma Sci. 1:60- 67.
28. Seymour AA, Sheldon JH, Smith PL, Asaad M, Rogers WL. 1994. Potentiation of the renal responses to bradykinin by inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in anesthetized dogs. J. Pharmacol. Exp. Ther. 269:263-270.
29. Bock TK, Muller BW. 1994. A novel assay to determine the hemolytic activity of drugs incorporated in colloidal carrier systems. Pharm. Res. 11:589 -591.
30. Mookerjee Basu J, Mookerjee A, Banerjee R, Saha M, Singh S, Naskar K, Tripathy G, Sinha PK, Pandey K, Sundar S, Bimal S, Das PK, Choudhuri SK, Roy S. 2008. Inhibition of ABC transporters abolishes antimony resistance in Leishmania infection. Antimicrob. Agents Chemother. 52:1080 -1093.
31. Gupta S, Dube A, Vyas SP. 2007. Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis. J. Drug Target. 15:437- 444.
32. Manandhar KD, Yadav TP, Prajapati VK, Kumar S, Rai M, Dube A, Srivastava ON, Sundar S. 2008. Antileishmanial activity of nanoamphotericin B deoxycholate. J. Antimicrob. Chemother. 62:376 -380.
33. Lawrence MJ, Rees GD. 2000. Microemulsion-based media as novel drug delivery systems. Adv. Drug Deliv. Rev. 45:89 -121.
34. Minkov I, Ivanova T, Panaiotov I, Proust J, Saulnier P. 2005. Reorganization of lipid nanocapsules at air-water interface. Part I. Kinetics of surface film formation. Colloids Surf. B Biointerfaces 45:14 -23.
35. Minkov I, Ivanova T, Panaiotov I, Proust J, Saulnier P. 2005. Reorganization of lipid nanocapsules at air-water interface. Part 2. Properties of the formed surface film. Colloids Surf. B Biointerfaces 44:197-203.
36. Yilmaz E, Borchert HH. 2005. Design of a phytosphingosine-containing, positively-charged nanoemulsion as a colloidal carrier system for dermal application of ceramides. Eur. J. Pharm. Biopharm. 60:91-98.
37. Behrend O, Ax K, Schubert H. 2000. Influence of continuous phase viscosity on emulsification by ultrasound. Ultrason. Sonochem. 7:77- 85.
38. Vandervoort J, Ludwig A. 2002. Biocompatible stabilizers in the preparation of PLGA nanoparticles: a factorial design study. Int. J. Pharm. 238: 77-92.
39. Kunjachan S, Gupta S, Dwivedi AK, Dube A, Chourasia MK. 2011. Chitosan-based macrophage-mediated drug targeting for the treatment of experimental visceral leishmaniasis. J. Microencapsul. 28:301-310.
40. Anton N, Benoit JP, Saulnier P. 2008. Design and production of nanoparticles formulated from nano-emulsion templates - a review. J. Control. Release 128:185-199.
41. Washington C, Lance M, Davis SS. 1993. Toxicity of amphotericin B emulsion formulations. J. Antimicrob. Chemother. 31:806-808.
42. Mahmud H, Mauro D, Qadri SM, Foller M, Lang F. 2009. Triggering of suicidal erythrocyte death by amphotericin B. Cell. Physiol. Biochem. 24: 263-270.
43. Jumaa M, Furkert FH, Muller BW. 2002. A new lipid emulsion formulation with high antimicrobial efficacy using chitosan. Eur. J. Pharm. Biopharm. 53:115-123.
44. Ueno H, Mori T, Fujinaga T. 2001. Topical formulations and wound healing applications of chitosan. Adv. Drug Deliv. Rev. 52:105-115.
45. Mori T, Okumura M, Matsuura M, Ueno K, Tokura S, Okamoto Y, Minami S, Fujinaga T. 1997. Effects of chitin and its derivatives on the proliferation and cytokine production of fibroblasts in vitro. Biomaterials 18:947-951.
46. Gangneux JP, Sulahian A, Garin YJ, Farinotti R, Derouin F. 1996. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome. Antimicrob. Agents Chemother. 40:1214 -1218.
47. Yardley V, Croft SL. 2000. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int. J. Antimicrob. Agents 13:243-248.
48. Schmidt HH, Warner TD, Nakane M, Forstermann U, Murad F. 1992. Regulation and subcellular location of nitrogen oxide synthases in RAW264.7 macrophages. Mol. Pharmacol. 41:615- 624.
49. Samant M, Gupta R, Kumari S, Misra P, Khare P, Kushawaha PK, Sahasrabuddhe AA, Dube A. 2009. Immunization with the DNAencoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis. J. Immunol. 183:470-479.
50. Porporatto C, Bianco ID, Riera CM, Correa SG. 2003. Chitosan induces different L-arginine metabolic pathways in resting and inflammatory macrophages. Biochem. Biophys. Res. Commun. 304:266 -272.
51. Basu R, Bhaumik S, Basu JM, Naskar K, De T, Roy S. 2005. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J. Immunol. 174:7160 -7171.
52. Gifawesen C, Farrell JP. 1989. Comparison of T-cell responses in selflimiting versus progressive visceral Leishmania donovani infections in golden hamsters. Infect. Immun. 57:3091-3096.
53. Kenney RT, Sacks DL, Gam AA, Murray HW, Sundar S. 1998. Splenic cytokine responses in Indian kala-azar before and after treatment. J. Infect. Dis. 177:815- 818.
54. Melby PC, Tryon VV, Chandrasekar B, Freeman GL. 1998. Cloning of Syrian hamster (Mesocricetus auratus) cytokine cDNAs and analysis of cytokine mRNA expression in experimental visceral leishmaniasis. Infect. Immun. 66:2135-2142.